UkraineTuberculosis profile
Population  2016 44 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.2 (4.2–4.3) 9.5 (9.4–9.6)
Mortality (HIV+TB only) 2 (1.3–2.9) 4.6 (3–6.4)
Incidence  (includes HIV+TB) 39 (25–55) 87 (56–124)
Incidence (HIV+TB only) 8.1 (5.2–12) 18 (12–26)
Incidence (MDR/RR-TB)** 21 (16–26) 47 (37–58)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 2 (1.2–2.8) 9.3 (5.6–13) 11 (6.9–16)
Males 2.3 (1.4–3.2) 25 (15–35) 27 (17–38)
Total 4.4 (2.7–6.1) 34 (21–48) 39 (25–55)
TB case notifications, 2016  
Total cases notified 34 088
Total new and relapse 29 052
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 97%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 69%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 75% (53–120)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.17 (0.11–0.24)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 5 832 21%
          - on antiretroviral therapy 3 945 68%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  10 000
(10 000–11 000)
Estimated % of TB cases with MDR/RR-TB 27% (26–27) 47% (46–48)  
% notified tested for rifampicin resistance 59% 72% 21 637
MDR/RR-TB cases tested for resistance to second-line drugs   8 651
Laboratory-confirmed cases MDR/RR-TB: 8 651, XDR-TB: 1 195
Patients started on treatment **** MDR/RR-TB: 8 756, XDR-TB: 1 429
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 75% 23 892
Previously treated cases, excluding relapse, registered in 2015 57% 3 656
HIV-positive TB cases registered in 2015 63% 4 597
MDR/RR-TB cases started on second-line treatment in 2014 46% 7 174
XDR-TB cases started on second-line treatment in 2014 25% 1 097
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 52%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
12% (11–14)
TB financing, 2017  
National TB budget (US$ millions) 52
Funding source: 71% domestic, 16% international, 13% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-16 Data: www.who.int/tb/data